NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00957229,To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS),https://clinicaltrials.gov/study/NCT00957229,GDC-0449,COMPLETED,The purpose of this study is to reduce the number of new surgically eligible BCCs by 50% appearing during month 3-18 of medication ingestion.,YES,Basal Cell Nevus Syndrome|Gorlin Syndrome,DRUG: GDC-0449,"Number of New Surgically Eligible Basal-cell Carcinomas, Number of new surgically eligible basal-cell carcinomas per patient per year, 3 months of receiving study drug","Change in Size of the Existing Carcinomas, Expressed as the Sum of Cumulative Diameters in Millimeters Over an 18 Month Period, Baseline and 18 months|Number of New Surgically Eligible Basal-cell Carcinomas After Stopping Vismodegib Treatment, The number of new surgically eligible basal-cell carcinomas per patient per month is reported., These five patients were given placebo for a mean of 7.4 months (SD 2.3). After receiving vismodegib for a mean of 13.8 months (SD 6.8) and then discontinuing vismodegib for a mean of 11.8 months (SD 7.9) the new basal-cell carcinoma rate is reported.",,UCSF Benioff Children's Hospital Oakland,"Genentech, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE2,41,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-026|SHH-4685s,2009-08,2014-01,2014-01,2009-08-12,2021-01-11,2021-01-11,"Children's Hospital Oakland Research Institiute, Oakland, California, 94609, United States|Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, 10032, United States",
